Latest Intellectual Property News

Island Pharmaceuticals has cleared a major regulatory hurdle with the US FDA, confirming a clinical development path for its antiviral Galidesivir under the Animal Rule. Backed by a $9 million capital raise and strategic partnerships, the company is poised for potential US government procurement and biodefence market entry.

Biome Australia has taken a significant step in its innovation journey by filing a patent for its next generation probiotic strain BMB18, with a clinical trial set to begin in Q4 FY26 in partnership with La Trobe University.

AdNeo (ASX:AD1) delivered its first positive operating cash flow quarter since its 2025 transformation, driven by strong revenue growth across all divisions and a growing $8m tender pipeline. The company advances its AI-first strategy while managing costs and acquisitions.

Imricor Medical Systems updates its SEC Form 10 with minor SEC-driven revisions as it pushes forward with FDA clearances and clinical trials, reporting a $25.3 million net loss in 2025 amid early-stage commercialisation.

Diatreme Resources reported a $745,000 net loss for FY 2025 but strengthened its financial footing through asset sales and an IPO stake. The company’s Northern Silica Project and Cyclone Zircon Project showed significant technical progress, while a major Cape Flattery asset sale aims to streamline operations and unlock funding.

Invex Therapeutics reported promising preclinical findings on Exenatide’s effects in a human Alzheimer's disease model, alongside a steady cash position and reduced operating outflows in Q3 FY26.

Felix Group Holdings reported a 47% surge in total ARR to $12.7 million in Q3 FY26, driven by the Nexvia acquisition and enterprise expansion. The company is progressing AI platform enhancements and completed a key leadership renewal with new Chairman and CEO appointments.

Ainsworth Game Technology’s FY25 results reveal a mixed bag: a 9% dip in underlying profit to $21.1 million, a hefty $43.1 million goodwill impairment tied to North America, and a strategic pivot with a new acting CEO. Strong Asia Pacific growth and new product launches contrast with margin pressures and a shrinking cash position.

Light & Wonder has been hit with a class action lawsuit in Victoria alleging misleading statements about its Dragon Train game, targeting shareholders who bought Chess Depositary Interests between May 2023 and September 2024. The company has pledged a vigorous defence amid ongoing legal challenges.

BPH Global’s Indonesian arm has entered Stage 2 of its collaboration with Indonesia’s National Research and Innovation Agency to develop fucoidan extraction technology and a powdered supplement prototype, targeting commercialisation within months.

Iron Road Ltd faces headwinds in securing partners for its Central Eyre Iron Project amid market and energy volatility, delays drilling at Mulgathing due to flooding, but reports promising heavy mineral sands results and evolving land option dynamics at Cape Hardy.

Racura Oncology has detailed how its lead drug candidate, (E,E)-bisantrene, silences the cancer-driving MYC gene by stabilising G-quadruplex DNA structures, providing critical preclinical validation ahead of ongoing clinical trials.